More than 75 EMIF team members gathered in Budapest March 14-16, 2016 to not only share status updates on the ongoing work, but also discuss new joint AD/Metabolic scientific questions to be addressed using the EMIF framework.

Overall, tremendous progress was shown for both research projects, with many more exciting results being underway and opportunities for further collaboration identified. In particular the overlap between AD and metabolic disorders, due to inflammation, such as in Diabetes Mellitus Type 2, has provided opportunities for shared work.